KLK3 and neoplasm: The primary endpoint was composite response rate defined as either an objective radiological response (ORR) by response evaluation criteria in solid tumours 1.1 (RECIST 1.1), a decline in prostate specific antigen (PSA) level of at least 50% (PSA50), and/or conversion in circulating tumour cell (CTC) count from ≥5 cells/7.5 mL of blood to <5 cells/7.5 mL of blood, confirmed in a second reading 4 or more weeks apart [3,6].